JNJ · News · 20261021N

Oncology Pipeline Progress

JOHNSON & JOHNSON · 2026-10-21 · Importance 24 · Surprise 24

Johnson & Johnson is identified as a leading participant in the multiple-myeloma treatment pipeline. TECVAYLI is being evaluated in combination with DARZALEX FASPRO, with development moving toward earlier lines of treatment. The broader market includes more than 75 companies developing over 80 multiple-myeloma therapies. Rising global multiple-myeloma prevalence is supporting continued development activity.